IRCT20190210042676N33
Recruiting
Phase 2
Clinical study to evaluate the safety and efficacy of Lunagel 2.5 dermal filler (Nikan Teb Kimia CO) for correction of moderate to severe nasolabial fold
ikan Teb Kimia CO0 sites30 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- ikan Teb Kimia CO
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •18 \-65 years old men and women
- •Moderate to severe nasolabial folds based on Allergan criteria.
- •The opportunity to accompany the visit programs and study process
- •Signing the informed consent form and agree to a 6\-month follow\-up.
Exclusion Criteria
- •Cosmetic facial procedures (chemical peel, laser, radio frequency, dermabrasion, ablative or non\-ablative procedures), Botox) in the lower 2/3 of the face, within 3 months prior to study entry
- •Previous hyaluronic acid (HA)\-based dermal filler treatment(s) injected within the last 12 months prior to enrollment.
- •Planning to undergo any of these procedures at any time during the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Clinical study to evaluate the safety and efficacy of cinnamon in the management of non-alcoholic fatty liver diseaseHealth Condition 1: K760- Fatty (change of) liver, not elsewhere classifiedCTRI/2021/03/032039Central council for research in Unani medicine New dehli60
Completed
N/A
To study the effect of Tab HFO-O2 in fatty individuals.CTRI/2016/07/007067Baidyanath Bhavan Pvt Ltd
Active, Not Recruiting
Phase 3
A Clinical Study to Evaluate the Safety and Efficacy of Livercure Tablets on Patients with Liver Cirrhosis.Health Condition 1: K745- Biliary cirrhosis, unspecifiedHealth Condition 2: K745- Biliary cirrhosis, unspecifiedCTRI/2022/07/043725Jammi Pharmaceuticals Pvt Ltd
Completed
Phase 2
A study for Under eye dark circlesCTRI/2022/09/045732Transformative Learning Solutions Pvt Ltd32
Active, Not Recruiting
N/A
Clinical study to evaluate the efficacy and safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in adults. - N/AEUCTR2005-003552-35-DEOctapharma AG116